Studies have demonstrated the potential to detect and quantify TERT mutations in blood-based ctDNA from patients with melanoma (27) and brain tumors (28) and correlated detection of TERT promoter mutations with unfavorable response to first-line treatment regimens containing immunotherapy to treat hepatocellular carcinoma (29, 30). This evidence concerns the gene TERT and brain neoplasm.